Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

Journal:

The Lancet Oncology

Published:

2025-08-12

DOI:

10.1016/s1470-2045(25)00352-3

Affiliations:

19

Authors:

19

Go to article

Institutions	Authors	Share
Amgen, United States of America (USA)	3.000000	0.16
University of Pisa (UNIPI), Italy	1.000000	0.05
Amgen (Europe) GmbH, Switzerland	1.000000	0.05
Kyushu Cancer Center, Japan	1.000000	0.05
Fondazione Poliambulanza Istituto Ospedaliero, Italy	1.000000	0.05
National and Kapodistrian University of Athens (UOA), Greece	1.000000	0.05
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.05
National Cancer Center Hospital East, Japan	1.000000	0.05
Georges Pompidou European Hospital (HEGP), France	1.000000	0.05
City of Hope Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
Asan Medical Center (AMC), South Korea	1.000000	0.05
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	1.000000	0.05
Hospital de la Santa Creu i Sant Pau, Spain	1.000000	0.05
Charité - University Medicine Berlin, Germany	1.000000	0.05
National Institute of Cancer (INCan), Mexico	1.000000	0.05
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.05
Catholic University of the Sacred Heart (UCSC), Italy	0.500000	0.03
Agostino Gemelli University Polyclinic, Italy	0.500000	0.03

Interested in Oncology and Carcinogenesis?